Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Schizophrenia

Free Subscription 22.07.2024 1 Mol Psychiatry 1 Neuropsychopharmacology 2 PLoS One 2 Psychiatry Res 22 Schizophr Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Mol Psychiatry

1. FORNARO M, Caiazza C, Billeci M, Berk M, et al
   Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis "Nutra NMA SCZ".
   Mol Psychiatry. 2024 Jul 18. doi: 10.1038/s41380-024-02645.
   PubMed         Abstract available
   
   

   
   Neuropsychopharmacology

2. SMUCNY J, Carter CS
   Is treatment-resistant schizophrenia a neuroimmune condition? Meta-analytic evidence from magnetic resonance spectroscopy.
   Neuropsychopharmacology. 2024 Jul 18. doi: 10.1038/s41386-024-01932.
   PubMed        
   
   

   
   PLoS One

3. HUSAIN MO, Hawke LD, Lu Y, Kozloff N, et al
   A mixed-methods study to evaluate the feasibility and preliminary efficacy of delivering the optimal health program (OHP) for youth at clinical high risk (CHR) for psychosis: A study protocol.
   PLoS One. 2024;19:e0306968.
   PubMed         Abstract available
   
   
4. MATHIS WS, Ferrara M, Cahill J, Karmani S, et al
   TimelinePTC: Development of a unified interface for pathways to care collection, visualization, and collaboration in first episode psychosis.
   PLoS One. 2024;19:e0302116.
   PubMed         Abstract available
   
   

   
   Psychiatry Res

5. WANNAN CMJ, Eratne D, Santillo AF, Malpas C, et al
   Plasma neurofilament light protein is differentially associated with age in individuals with treatment-resistant schizophrenia and bipolar affective disorder compared to controls.
   Psychiatry Res. 2024;339:116073.
   PubMed         Abstract available
   
   
6. SIDDI S, Ochoa S, Laroi F, Lincoln TM, et al
   A cross-national investigation of psychosis-like experiences in five European countries included in the E-CLECTIC study: Psychometric challenges in studying their measurement.
   Psychiatry Res. 2024;339:116072.
   PubMed         Abstract available
   
   

   
   Schizophr Res

7. THIBAULT M, Romain AJ, Tessier C, Theagene JMJ, et al
   Feasibility and Acceptability of a Physical Activity Group Program Using telerehabilitation during the COVID-19 Pandemic in Multiple early Intervention for Psychosis Services.
   Schizophr Res. 2024;270:451-458.
   PubMed         Abstract available
   
   
8. LUI SSY, Lam EHY, Wang LL, Leung PBM, et al
   Negative symptoms in treatment-resistant schizophrenia and its relationship with functioning.
   Schizophr Res. 2024;270:459-464.
   PubMed         Abstract available
   
   
9. BARNBY JM, Haslbeck JMB, Rosen C, Sharma R, et al
   Modelling the longitudinal dynamics of paranoia in psychosis: A temporal network analysis over 20 years.
   Schizophr Res. 2024;270:465-475.
   PubMed         Abstract available
   
   
10. LIU L, Ren D, Li K, Ji L, et al
    Unraveling schizophrenia's genetic complexity through advanced causal inference and chromatin 3D conformation.
    Schizophr Res. 2024;270:476-485.
    PubMed         Abstract available
    
    
11. ZAMPERONI G, Tan EJ, Sumner PJ, Rossell SL, et al
    Exploring the conceptualisation, measurement, clinical utility and treatment of formal thought disorder in psychosis: A Delphi study.
    Schizophr Res. 2024;270:486-493.
    PubMed         Abstract available
    
    
12. CORBERA S, Wexler BE, Bell MD, Pittman B, et al
    Disentangling negative and positive symptoms in schizophrenia and autism spectrum disorder.
    Schizophr Res. 2024;271:1-8.
    PubMed         Abstract available
    
    
13. DWYER GE, Johnsen E, Hugdahl K
    NMDAR dysfunction and the regulation of dopaminergic transmission in schizophrenia.
    Schizophr Res. 2024;271:19-27.
    PubMed         Abstract available
    
    
14. LATRECHE I, Slatnia S, Kazar O, Harous S, et al
    Identification and diagnosis of schizophrenia based on multichannel EEG and CNN deep learning model.
    Schizophr Res. 2024;271:28-35.
    PubMed         Abstract available
    
    
15. DROSOS P, Johnsen E, Bartz-Johannessen CA, Larsen TK, et al
    Remission in schizophrenia spectrum disorders: A randomized trial of amisulpride, aripiprazole and olanzapine.
    Schizophr Res. 2024;271:9-18.
    PubMed         Abstract available
    
    
16. VARATHAN A, Senthooran S, Jeyananthan P
    Role of different omics data in the diagnosis of schizophrenia disorder: A machine learning study.
    Schizophr Res. 2024;271:38-46.
    PubMed         Abstract available
    
    
17. BIONDI M, Marino M, Mantini D, Spironelli C, et al
    Unveiling altered connectivity between cognitive networks and cerebellum in schizophrenia.
    Schizophr Res. 2024;271:47-58.
    PubMed         Abstract available
    
    
18. MACHIRAJU SN, Wyss J, Light G, Braff DL, et al
    Novel N100 area reliably captures aberrant sensory processing and is associated with neurocognition in early psychosis.
    Schizophr Res. 2024;271:71-80.
    PubMed         Abstract available
    
    
19. LAK M, Jafarpour A, Shahrbaf MA, Lak M, et al
    The effect of physical exercise on cognitive function in schizophrenia patients: A GRADE assessed systematic review and meta-analysis of controlled clinical trials.
    Schizophr Res. 2024;271:81-90.
    PubMed         Abstract available
    
    
20. LISBOA JRF, Costa O, Pakes GH, Colodete DAE, et al
    Perineuronal net density in schizophrenia: A systematic review of postmortem brain studies.
    Schizophr Res. 2024;271:100-109.
    PubMed         Abstract available
    
    
21. KREIS I, Lagerberg TV, Wold KF, Asbo G, et al
    Behind the heterogeneity in the long-term course of first-episode psychosis: Different psychotic symptom trajectories are associated with different patterns of cannabis and stimulant use.
    Schizophr Res. 2024;271:91-99.
    PubMed         Abstract available
    
    
22. FEOLA B, Flook EA, Seo DJ, Fox V, et al
    Altered brain and physiological stress responses in early psychosis.
    Schizophr Res. 2024;271:112-119.
    PubMed         Abstract available
    
    
23. LI R, Cao M, Fu D, Wei W, et al
    Deciphering language disturbances in schizophrenia: A study using fine-tuned language models.
    Schizophr Res. 2024;271:120-128.
    PubMed         Abstract available
    
    
24. CARRION RE, Ku BS, Dorvil S, Auther AM, et al
    Neurocognition in adolescents and young adults at clinical high risk for psychosis: Predictive stability for social and role functioning.
    Schizophr Res. 2024;271:129-137.
    PubMed         Abstract available
    
    
25. AL-CHALABI N, Nader G, Fischer C, Graff A, et al
    Effect of DNA methylation and AUDIT-C polygenic scores on alcohol use disorder comorbidity in psychoses: No evidence of epigenetic basis of polygenic risk.
    Schizophr Res. 2024;271:138-141.
    PubMed        
    
    
26. KOSTER M, van der Pluijm M, van de Giessen E, Schrantee A, et al
    The association of tobacco smoking and metabolite levels in the anterior cingulate cortex of first-episode psychosis patients: A case-control and 6-month follow-up (1)H-MRS study.
    Schizophr Res. 2024;271:144-152.
    PubMed         Abstract available
    
    
27. CHINTOH A, Liu L, Braun A, Akseer S, et al
    Sex differences in clinical presentation in youth at high risk for psychosis who transition to psychosis.
    Schizophr Res. 2024;271:153-160.
    PubMed         Abstract available
    
    
28. KENNEDY KP, Zito MF, Marder SR
    Does relapse cause illness progression in first-episode psychosis? A review.
    Schizophr Res. 2024;271:161-168.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.